Dr Reddy's laboratories expects to launch the generic version of Copaxone in the US market during the first half of next fiscal.
Copaxone(glatiramer acetate injection) isa multi-billion dollar drug anda prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis.
"We are on track to respond to FDA on the queries received in Jan/Feb18 over next couple of months. Post that, we are likely to get new (target action date) TAD/Goal Date."
Disclaimer: No Business Standard Journalist was involved in creation of this content